Vcare PharmaTech Ranked in Tier 1 of "Top 100 Chinese Innovative Pharmaceutical Seed Enterprises 2026" for Two Consecutive Years
Published Time:
2026-06-29 17:39
Source:
On June 26, the authoritative ranking of the "Top 100 Chinese Innovative Pharmaceutical Seed Enterprises 2026" (Seed 100 List) was officially released. Relying on its technological moat built by AI-driven original innovation, a complete independent R&D system, a tiered global innovation pipeline, marketed innovative drug achievements and comprehensive global patent portfolio layout, Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech) has once again been listed in Tier 1 of the ranking, marking its sixth consecutive year on the Seed 100 List.
Vcare PharmaTech has secured a spot on the Seed 100 List for six straight years since 2021. It entered Tier 1 for the first time in 2025 and retained this position this year. Its consistent listing and Tier 1 standing serve as high recognition of the company’s long-term dedication to developing innovative medicines and leading therapies, and fully validate its comprehensive strength and steady growth in technological innovation and translation, new drug research as well as clinical development.
AI Empowerment Fuels Differentiated Original Drug Design
Upholding independent incubation and original innovation, Vcare PharmaTech actively integrates cutting-edge technologies with new drug discovery, with a strategic focus on AI-enabled differentiated original molecular design. Artificial intelligence technology accelerates core R&D workflows including target identification, molecular design and candidate compound optimization, greatly boosting R&D efficiency and clinical success rates. This forward-looking strategy has built robust technological barriers across the entire innovative drug development cycle, and further consolidated the deeply collaborative industrial chain covering technology research, drug development and commercial manufacturing.
Accelerated Rollout of Innovation Pipeline; First Anti-Tumor Targeted Drug Granted Marketing Approval
Early June witnessed a landmark breakthrough in Vcare PharmaTech’s innovative drug development pipeline: VELMARTO® (Eratrectinib), the company’s self-developed Class 1 small-molecule targeted anti-tumor drug, obtained marketing approval from the NMPA. This milestone signals Vcare PharmaTech’s official transition from an R&D-focused biotech firm to an integrated enterprise covering both research and commercialization.
Meanwhile, the company’s innovation pipeline has delivered multiple key advances: one candidate drug has formally accepted NDA approval, several candidates are undergoing Phase II and Phase III clinical trials, and a batch of pre-clinical innovative drug programs are under continuous incubation. The tiered pipeline covers core therapeutic areas including oncology, cardiovascular and cerebrovascular diseases, as well as inflammatory and autoimmune disorders, forming a globally competitive product portfolio.
Address Unmet Clinical Needs via Differentiated R&D to Forge Global Competitiveness
Moving forward, Vcare PharmaTech will stay committed to its strategic mission of "addressing unmet clinical needs through differentiated innovation". The company will further expand its innovative drug pipeline, leverage the technical strengths of AI-powered original discovery, and speed up the research, translational development and commercial launch of more Class 1 innovative medicines. It aims to build a diversified innovative drug portfolio with solid technological barriers and outstanding clinical competitiveness across multiple disease areas, deliver superior treatment options for patients worldwide, and fuel high-quality growth of China’s pharmaceutical innovation sector.
About the Seed 100 List
The Seed 100 List selects enterprises representing the innovation potential of China’s pharmaceutical industry. Compiled by authoritative industrial media E Pharma Manager, the ranking adopts an evaluation framework centered on innovation foundation, innovation process and innovation output. Based on Clarivate’s Cortellis competitive intelligence, clinical trial data and Derwent Innovation patent database, evaluators analyze metrics including the number of granted patents, total patent citations, ongoing clinical trial programs, and approved/marketed new medicines to shortlist the top 100 innovative pharmaceutical enterprises.
Previous Page
Related News
12
2026
/
05
Recently, Jiangsu Vcare PharmaTech Co.,Ltd. (Jiangsu Vcare) announced that VC005 Topical Gel, its self-developed second-generation highly selective JAK1 inhibitor, has completed the enrollment of the first patient in the phase III clinical trial for the treatment of mild-to-moderate atopic dermatitis (AD).
View Details
07
2026
/
05
Recently, VC005 Topical Gel, a second-generation highly selective JAK1 inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), has officially obtained the IND approval from the CDE of the NMPA. The product is intended for the topical treatment of non-segmental vitiligo.
View Details
25
2026
/
03
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) announced a major milestone breakthrough in the Phase III clinical study of VC005 Tablets, its independently developed second-generation highly selective JAK1 inhibitor for the oral treatment of moderate-to-severe AD, achieved positive topline results for the primary endpoint. This key milestone marks a decisive step forward for VC005 Tablets toward market launch and provides new therapeutic hope for numerous patients with moderate-to-severe AD.
View Details
06
2026
/
03
Recently, VC005 Topical Gel, a second-generation highly selective JAK1 inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), has received ethical approval for its Phase III clinical trial. The Phase III study for the treatment of mild-to-moderate atopic dermatitis (AD) will soon be initiated, marking a pivotal milestone as this differentiated innovative topical drug advances into the confirmatory clinical stage.
View Details
06
2026
/
02
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) has successfully completed patient enrollment in a Phase II clinical trial of VC005 Tablets, an independently developed second-generation highly selective JAK1 inhibitor, for the oral administration of non-segmental vitiligo (NSV).
View Details
02
2026
/
02
Recently, a major R&D milestone has been achieved for VC005 Tablets, a second-generation highly selective JAK1 inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare). The project has officially obtained IND approval from the CDE of the NMPA of China, which is intended for the oral treatment of alopecia areata, bringing a brand-new therapeutic hope to patients suffering from hair loss.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
苏公网安备32011202001742号
Powerby：www.300.cn nanjing.300.cn